Salix Pharmaceuticals Given Outperform Rating at Keefe, Bruyette & Woods (SLXP)
Salix Pharmaceuticals (NASDAQ:SLXP)‘s stock had its “outperform” rating restated by equities research analysts at Keefe, Bruyette & Woods in a research note issued to investors on Friday. They currently have a $147.00 price objective on the stock, down from their previous price objective of $160.00. Keefe, Bruyette & Woods’ price target suggests a potential upside of 14.58% from the company’s current price.
Salix Pharmaceuticals (NASDAQ:SLXP) opened at 128.29 on Friday. Salix Pharmaceuticals has a 52-week low of $64.93 and a 52-week high of $141.81. The stock has a 50-day moving average of $132.0 and a 200-day moving average of $113.1. The company has a market cap of $8.135 billion and a price-to-earnings ratio of 113.47.
Salix Pharmaceuticals (NASDAQ:SLXP) last announced its earnings results on Thursday, August 7th. The company reported $1.59 EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.69 by $0.10. The company had revenue of $382.00 million for the quarter, compared to the consensus estimate of $397.06 million. During the same quarter in the prior year, the company posted $0.87 earnings per share. The company’s quarterly revenue was up 62.3% on a year-over-year basis. Analysts expect that Salix Pharmaceuticals will post $6.53 EPS for the current fiscal year.
A number of other analysts have also recently weighed in on SLXP. Analysts at Mizuho cut their price target on shares of Salix Pharmaceuticals from $205.00 to $195.00 in a research note on Friday. They now have a “buy” rating on the stock. Separately, analysts at Cantor Fitzgerald upgraded shares of Salix Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday. They now have a $157.00 price target on the stock, up previously from $121.00. Finally, analysts at Deutsche Bank initiated coverage on shares of Salix Pharmaceuticals in a research note on Tuesday, July 22nd. They set a “hold” rating and a $139.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and twelve have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $134.15.
Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.